ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
64 099,01
1,93%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aclaris Therapeutics Inc (ACRS)

  7. Aclaris Therapeutics Inc (ACRS) Actualités

ACRS Aclaris Therapeutics Inc

1,38
0,07 (5,34%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Aclaris Therapeutics Inc ACRS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,07 5,34% 1,38 06:00:01
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,31 1,31 1,40 1,36 1,31
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202413:00GLOBEAclaris Therapeutics to Announce First Quarter 2024..
23/4/202414:00PRNUSFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C)..
05/3/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202413:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:14EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEAclaris Therapeutics Reports Fourth Quarter and Full Year..
15/2/202402:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202420:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202420:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:31EDGAR2Form 8-K/A - Current report: [Amend]
05/2/202422:30EDGAR2Form 8-K - Current report
19/1/202413:30EDGAR2Form 8-K - Current report
16/1/202413:00GLOBEAclaris Therapeutics Announces Leadership Changes and..
10/1/202413:00GLOBEAclaris Therapeutics Announces Top-line Results from 4-Week..
03/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202322:15EDGAR2Form 8-K - Current report
19/12/202322:01GLOBEAclaris Therapeutics Provides Corporate Update
05/12/202322:01GLOBEAclaris Therapeutics Announces Patent License Agreement with..
13/11/202313:42EDGAR2Form 8-K - Current report
13/11/202313:00GLOBEAclaris Therapeutics Announces Top-line Results from 12-Week..
06/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202313:15EDGAR2Form 8-K - Current report
06/11/202313:00GLOBEAclaris Therapeutics Reports Third Quarter 2023 Financial..
25/10/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202322:06EDGAR2Form 144 - Report of proposed sale of securities
03/10/202313:00GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
20/9/202313:00GLOBEAclaris Therapeutics to Participate in the 2023 Cantor..
18/9/202314:00EDGAR2Form 8-K - Current report
18/9/202313:00GLOBEAclaris Therapeutics Announces Positive Results from Phase 1..
07/9/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202323:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202322:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202322:20EDGAR2Form 144 - Report of proposed sale of securities
07/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202313:15EDGAR2Form 8-K - Current report
07/8/202313:00GLOBEAclaris Therapeutics Reports Second Quarter 2023 Financial..
03/8/202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202322:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202313:01GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
02/6/202313:00GLOBEAclaris Therapeutics to Participate in Two June Healthcare..
08/5/202313:00GLOBEAclaris Therapeutics Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
ACRS
Aclaris Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés